BACKGROUND: A surrogate marker is a variable commonly used in clinical trials to guide treatment decisions when the outcome of ultimate interest is not available. A good surrogate marker is one where the treatment effect on the surrogate is a strong predictor of the effect of treatment on the outcome. We review the situation when there is one treatment delivered at baseline, one surrogate measured at one later time point, and one ultimate outcome of interest and discuss new issues arising when variables are time-varying. METHODS: Most of the literature on surrogate markers has only considered simple settings with one treatment, one surrogate, and one outcome of interest at a fixed time point. However, more complicated time-varying settings ...
When evaluating the effectiveness of a treatment, policy, or intervention, the desired measure of ef...
The last 20 years have seen lots of work in the area of surrogate marker validation, partly devoted ...
Two paradigms for the evaluation of surrogate markers in randomized clinical trials have been propos...
Randomized clinical trials with rare primary endpoints or long duration times are costly. Because of...
A surrogate marker (S) is often an intermediate physical or laboratory indicator in a disease progre...
Given the long follow-up periods that are often required for treatment or intervention studies, the ...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139917/1/sim7430.pdfhttps://deepblue.l...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
Motivated by increasing pressure for decision makers to shorten the time required to evaluate the ef...
Surrogate endpoints are desirable in clinical trials when primary endpoints are costly to obtain, di...
Thesis (Ph.D.)--Boston UniversityPLEASE NOTE: Boston University Libraries did not receive an Authori...
Clinical trials can be lengthy and costly, with new treatments taking more than a decade to become ...
Clinical trials with rare or distant outcomes are usually designed to be large in size and long term...
Various meta-analytical approaches have been applied to evaluate putative surrogate endpoints (S) of...
When evaluating the effectiveness of a treatment, policy, or intervention, the desired measure of ef...
The last 20 years have seen lots of work in the area of surrogate marker validation, partly devoted ...
Two paradigms for the evaluation of surrogate markers in randomized clinical trials have been propos...
Randomized clinical trials with rare primary endpoints or long duration times are costly. Because of...
A surrogate marker (S) is often an intermediate physical or laboratory indicator in a disease progre...
Given the long follow-up periods that are often required for treatment or intervention studies, the ...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139917/1/sim7430.pdfhttps://deepblue.l...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
Motivated by increasing pressure for decision makers to shorten the time required to evaluate the ef...
Surrogate endpoints are desirable in clinical trials when primary endpoints are costly to obtain, di...
Thesis (Ph.D.)--Boston UniversityPLEASE NOTE: Boston University Libraries did not receive an Authori...
Clinical trials can be lengthy and costly, with new treatments taking more than a decade to become ...
Clinical trials with rare or distant outcomes are usually designed to be large in size and long term...
Various meta-analytical approaches have been applied to evaluate putative surrogate endpoints (S) of...
When evaluating the effectiveness of a treatment, policy, or intervention, the desired measure of ef...
The last 20 years have seen lots of work in the area of surrogate marker validation, partly devoted ...
Two paradigms for the evaluation of surrogate markers in randomized clinical trials have been propos...